GlassScriptPhysician profile
Scott Merrill Pinter
NPI 1174527626
$3,559.47
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $76.92 · 2021: $471 · 2022: $468 · 2023: $538 · 2024: $1,084 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.66 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $631.24 | 2019-2025 | Eysuvis, Clareon, Rocklatan |
| Novartis Pharmaceuticals Corporation | $447.06 | 2019-2023 | |
| Rxsight INC | $265.72 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $214.38 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $200.51 | 2019-2022 | |
| Glaukos Corporation | $198.28 | 2022-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Mallinckrodt Hospital Products INC. | $177.09 | 2021-2025 | Acthar |
| Harrow Eye, LLC | $171.15 | 2023-2025 | Vevye, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $119.51 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $114.49 | 2019-2024 | |
| Astellas Pharma US INC | $114.05 | 2024-2025 | Izervay |
| Oyster Point Pharma, INC. | $111.55 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $110.24 | 2024-2025 | Xdemvy |
| Abbvie INC. | $107.74 | 2022-2025 | |
| Genentech USA, INC. | $77.46 | 2022-2025 | Vabysmo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $74.05 | 2023-2024 | Syfovre |
| Shire North American Group INC | $53.51 | 2019 | |
| Amgen INC. | $53.39 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $48.72 | 2021-2022 | |
| Dompe US, INC. | $47.49 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $41.78 | 2019-2021 | |
| Thea Pharma INC. | $40.38 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $38.32 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $35.91 | 2024-2025 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $24.62 | 2021 | |
| Horizon Therapeutics Plc | $20.90 | 2021 | |
| Quidel Corporation | $19.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.